4DMedical Issues New Shares Under Long-Term Incentive Plan, Confirms Regulatory Compliance

An update from 4DMedical Ltd ( (AU:4DX) ) is now available.

4DMedical has issued 1,583,776 fully paid ordinary shares following the exercise of options and restricted stock units under its Long Term Incentive Plan, with the issuance recorded in an Appendix 2A lodged with the ASX. The company has confirmed that these shares were issued without a prospectus under the Corporations Act disclosure exemptions and that it remains compliant with its financial reporting and continuous disclosure obligations, signaling routine equity-based remuneration rather than a capital-raising event.

By lodging a cleansing notice under section 708A(5)(e) of the Corporations Act, 4DMedical enables secondary trading of the new shares without further disclosure, indicating there is no excluded or undisclosed price-sensitive information related to this issuance. The move formalizes the governance and regulatory framework around its incentive plan, providing clarity and transparency for existing and potential shareholders about the nature and compliance status of the additional shares on issue.

The most recent analyst rating on (AU:4DX) stock is a Hold with a A$4.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.

More about 4DMedical Ltd

4DMedical Limited is an Australian medical technology company focused on lung health, developing imaging and diagnostic solutions aimed at improving assessment and management of respiratory conditions. The company is listed on the ASX under the ticker 4DX and operates across Australia and the United States, serving clinicians and healthcare providers in respiratory care markets.

Average Trading Volume: 6,896,428

Technical Sentiment Signal: Buy

Current Market Cap: A$2.41B

For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.